Key facts
- It has raised $410K; the latest was Early Stage VC ($410K) in Sep 2025.
- Notable investors include Innovatiefonds Noord-Holland.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for AviSia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for AviSia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AviSia Therapeutics
Developer of antigen-specific immunotherapies intended to treat autoimmune diseases. The company provides immune-modulating therapeutics, primarily focused on type 1 diabetes, enabling patients to have immune tolerance and reduced autoimmune activity while creating lifelong protection against such diseases.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2024
- Employees
- 4
- Website
- avisiatherapeutics.com/
- Ownership
- Privately Held (backing)
AviSia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AviSia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AviSia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.